Company investigating whether the illness may be a side effect of the vaccine
WEDNESDAY, Sept. 9, 2020 (HealthDay News) — A “potentially unexplained” illness in a participant has led AstraZeneca to halt a late-stage clinical trial of its COVID-19 vaccine.
The company is investigating whether the illness may be a side effect of the vaccine, the Associated Press reported. The pause in the study covers the United States and other countries where the vaccine is being tested. The health news site STAT said the possible side effect occurred in the United Kingdom, the AP reported.
“We are working to expedite the review of the single event to minimize any potential impact on the trial timeline,” AstraZeneca said in a statement.
Large, final-stage clinical trials of two other COVID-19 vaccines are underway in the United States, one from Moderna and the other from Pfizer and BioNTech. Those two vaccines work differently than the AstraZeneca vaccine, the AP reported.
Nearly 3 in 4 Older Adults Express Interest in Vaccine to Prevent Dementia
Updated COVID-19 Shot Beneficial for Those With Autoimmune Rheumatic Disease
Trends Reported in Vaccination Coverage for Adolescents for 2025
AAP Issues Recommendations for Pediatric RSV Vaccination in 2026-2027 Season
4CMenB Vaccine Confers Modest Protection Against Gonorrhea in Teens
AAP Releases Influenza Vaccine Recommendations for All Children 6 Months and Older
Adverse Event Risk Not Up With Same Day COVID-19, Flu Vaccination